KAITLIN OLSON: Open Payments
NPI 1477096477 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,124 in 10 payments from 10 companies in 2025. Trend: 2023 $83 · 2024 $599 · 2025 $1,124
Food & beverage: $1,124
| Company | Payments | Amount |
|---|---|---|
| Genmab U.S., Inc. | 1 | $125 |
| SOBI, INC | 1 | $124 |
| JAZZ PHARMACEUTICALS INC. | 1 | $123 |
| Agios Pharmaceuticals, Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $116 |
| AstraZeneca Pharmaceuticals LP | 1 | $112 |
| GlaxoSmithKline, LLC. | 1 | $110 |
| Merck Sharp & Dohme LLC | 1 | $105 |
| Syndax Pharmaceuticals, Inc. | 1 | $99 |
| Ipsen Biopharmaceuticals, Inc | 1 | $88 |
Products named: Tivdak, Vonjo, RYLAZE, PYRUKYND, OPDIVO, LYNPARZA, KEYTRUDA, REVUFORJ.
Industry payments across TX — which companies pay providers there.
